EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results

Jamie K Capal iD, David M Ritter iD, David Neal Franz, Molly Griffith, Kristn Currans, Bridget Kent, E Martina Bebin, Hope Northrup, Mary Kay Koenig, Tomoyuki Mizuno, Alexander A Vinks, Stephanie L Galandi und 8 weitere

Annals of the Child Neurology Society · 2024-06 · 2 (2) · 106-119

DOI: 10.1002/cns3.20070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of the Child Neurology Society, online erschienen am 22.04.2024. Verfasst von Jamie K Capal und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FDA HHS, NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Tuberous sclerosis complex (TSC) results from overactivity of the mechanistic target of rapamycin (mTOR). Sirolimus and everolimus are mTOR inhibitors that treat most facets of TSC but are understudied in infants. We sought to understand the safety and potential efficacy of preventative sirolimus in infants with TSC.

Methods

We conducted a phase 1 clinical trial of sirolimus, treating five patients until 12 months of age. Enrolled infants had to be younger than 6 months of age with no history of seizures and no clinical indication for sirolimus treatment. Adverse events (AEs), tolerability, and blood concentrations of sirolimus measured by tandem mass spectrometry were tracked through 12 months of age, and clinical outcomes (seizure characteristics and developmental profiles) were tracked through 24 months of age.

Results

There were 92 AEs, with 34 possibly, probably, or definitely related to treatment. Of those, only two were grade 3 (both elevated lipids) and all AEs were resolved by the age of 24 months. During the trial, 94% of blood sirolimus trough levels were in the target range (5–15 ng/mL). Treatment was well tolerated, with less than 8% of doses held because of an AE (241 of 2941). Of the five patients, three developed seizures (but were well controlled on medications) at 24 months of age. Of the five patients, four had normal cognitive development for age. One was diagnosed with possible autism spectrum disorder.

Interpretation

These results suggest that sirolimus is both safe and well tolerated by infants with TSC in the first year of life. Additionally, the preliminary work suggests a favorable efficacy profile compared with previous TSC cohorts not exposed to early sirolimus treatment. Results support sirolimus being studied as preventive treatment in TSC, which is now underway in a prospective phase 2 clinical trial (TSC‐STEPS).

Schlagwörter

Stichwörter der Autor:innen

safetyseizuressirolimustuberous sclerosis complex

Autor:innen und Institutionen

  • Department of Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Division of Neurology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Division of Behavioral Medicine and Clinical Psychology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Division of Speech-Language Pathology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Division of Medical Genetics, Department of Pediatrics, McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth) and Children's Memorial Hermann Hospital, Houston, TX, USA.

ORCID-Profile: Jamie K Capal, David M Ritter

Förderung

  • FDA HHS
  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • U.S. Food and Drug Administration

Zitieren

APA

Capal, J. K., Ritter, D. M., Franz, D. N., Griffith, M., Currans, K., Kent, B., Bebin, E. M., Northrup, H., Koenig, M. K., Mizuno, T., Vinks, A. A., Galandi, S. L., Zhang, W., Setchell, K. D. R., Kremer, K. M., Prada, C. M., Greiner, H. M., Holland-Bouley, K., Horn, P. S., & Krueger, D. A. (2024). Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results. Annals of the Child Neurology Society, 2(2), 106-119. https://doi.org/10.1002/cns3.20070

Vancouver

Capal JK, Ritter DM, Franz DN, Griffith M, Currans K, Kent B, et al. Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results. Annals of the Child Neurology Society. 2024;2(2):106-119. doi:10.1002/cns3.20070

BibTeX
@article{Capal2024,
  author = {Capal, Jamie K and Ritter, David M and Franz, David Neal and Griffith, Molly and Currans, Kristn and Kent, Bridget and Bebin, E Martina and Northrup, Hope and Koenig, Mary Kay and Mizuno, Tomoyuki and Vinks, Alexander A and Galandi, Stephanie L and Zhang, Wujuan and Setchell, Kenneth D R and Kremer, Kelly M and Prada, Carlos M and Greiner, Hansel M and Holland-Bouley, Katherine and Horn, Paul S and Krueger, Darcy A},
  title = {Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results},
  journal = {Annals of the Child Neurology Society},
  year = {2024},
  volume = {2},
  number = {2},
  pages = {106--119},
  doi = {10.1002/cns3.20070}
}
Kostenlos starten →